Increasing unusual call option volume: LU GSAT BBIO OPRA FNGR EVGO APLS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
KOL thinks Apellis Pharmaceuticals (APLS) issues with Syfovre 'likely solvable' - TD Cowen
July 17, 2023 4:22 PM EDTTD Cowen analyst Phil Nadeau weighed in on Apellis Pharmaceuticals (NASDAQ: APLS) after shares fell 38% after six cases of retinal vasculitis have been reported with Syfovre.
The analyst commented, "During TD Cowen Rounds @ Cleveland Clinic today we discussed the situation with a... More
Stifel on Apellis Pharmaceuticals (APLS): 'we expect this pressure to be short-lived'
July 17, 2023 1:06 PM EDTStifel analyst Annabel Samimy reiterated a Buy rating and $90.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).
The analyst comments "
The recent ASRS member notification has stoked new safety fears for Syfovre, with notification of six IOI events with retinal vasculitis, calculated... More
